Patient
SITE002-0025
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE002 (USA) (Dr. Nolan)
consented 2025-09-22
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 345); relationship: RELATED
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 324); relationship: NOT RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 266); relationship: RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 138); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 133); relationship: not assessed
Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-07-27 (study day 119); relationship: NOT RELATED; serious criteria: hospitalization
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-05-26 (study day 57); relationship: NOT RELATED
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-07 (study day 8); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.